Humacyte (NASDAQ:HUMA) Shares Down 6.2% – Should You Sell?

Shares of Humacyte, Inc. (NASDAQ:HUMA) fell 6.2% on Monday . The company traded as low as $5.31 and last traded at $5.42. 867,045 shares traded hands during trading, a decline of 63% from the average session volume of 2,357,155 shares. The stock had previously closed at $5.78.

Analyst Upgrades and Downgrades

HUMA has been the subject of a number of recent research reports. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humacyte has a consensus rating of “Buy” and an average target price of $11.00.

Humacyte Stock Performance

The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 5.41. The stock’s 50-day simple moving average is $5.45 and its 200 day simple moving average is $6.18.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, analysts predict that Humacyte, Inc. will post -1.18 EPS for the current fiscal year.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the sale, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,084,153 shares of company stock valued at $6,869,996 over the last three months. 11.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after buying an additional 896,415 shares during the last quarter. Millennium Management LLC increased its position in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Humacyte by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock valued at $3,924,000 after purchasing an additional 66,946 shares in the last quarter. Renaissance Technologies LLC grew its stake in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in Humacyte by 3,301.5% in the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after purchasing an additional 450,031 shares during the period. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.